Danes seek compromise on EU bioethics research programme
This article was originally published in Clinica
The Danish presidency of the European Union has drawn up a proposed compromise deal on bioethics in an aim to ensure there are no hitches to the progress of certain potentially controversial research programmes within the EU's Sixth Framework Programme (FP6). The FP6 programme, a five-year research programme beginning in 2003, focuses on many medical-related areas, including nanotechology, where medical testing of prosthetics and drug delivery are among the sectors most likely to benefit.
You may also be interested in...
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.